Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT03602560 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT03602560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03602560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
October 1, 2018
Completion date
February 16, 2020
Enrollment
265 (actual)
Sites
156

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cholangitis